October 2025 Amneal Pharmaceuticals commercially launched Brekiya® in the United States through specialty pharmacy channels, making the first DHE autoinjector broadly available for adults with migraine with or without aura.
May 2025 Amneal Pharmaceuticals received U.S. FDA approval for Brekiya® (dihydroergotamine mesylate) injection, the first ready-to-use DHE autoinjector approved for the acute treatment of migraine with or without aura in adults, expanding acute migraine treatment options.
May 2025 Satsuma Pharmaceuticals (a subsidiary of Shin Nippon Biomedical Laboratories) received U.S. FDA approval for Atzumi™ (dihydroergotamine nasal powder), the first DHE nasal powder approved for the acute treatment of migraine with or without aura in adults.
January 2025 Axsome Therapeutics received U.S. FDA approval for SYMBRAVO® (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults, expanding its prescription migraine treatment portfolio.